SDG 3. GOOD HEALTH & WELL-BEING BenevolentAI

BenevolentAI identifies novel target for ulcerative colitis and advances candidate to IND/CTA-enabling studies

rt.gif?NewsItemId=IO39838&Transmission_I

LONDON, Oct. 14, 2021 /PRNewswire/ — In a significant milestone for its (AI)-driven drug discovery platform, BenevolentAI has nominated a preclinical candidate for a novel ulcerative colitis target, and plans to advance the asset into clinical trials. Scientists deployed BenevolentAI’s…






Read more on PR Newswire:

You may also like

Comments are closed.